Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Change in Receivables: 2013-2025

Historic Change in Receivables for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Sep 2025 value amounting to $13.8 million.

  • Amphastar Pharmaceuticals' Change in Receivables rose 71.21% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year decrease of 67.33%. This contributed to the annual value of $21.7 million for FY2024, which is 16.92% down from last year.
  • Latest data reveals that Amphastar Pharmaceuticals reported Change in Receivables of $13.8 million as of Q3 2025, which was up 212.42% from -$12.3 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Change in Receivables registered a high of $23.2 million during Q1 2024, and its lowest value of -$12.3 million during Q2 2025.
  • Over the past 3 years, Amphastar Pharmaceuticals' median Change in Receivables value was $8.1 million (recorded in 2024), while the average stood at $5.2 million.
  • Its Change in Receivables has fluctuated over the past 5 years, first surged by 1,430.46% in 2022, then slumped by 428.82% in 2024.
  • Quarterly analysis of 5 years shows Amphastar Pharmaceuticals' Change in Receivables stood at $755,000 in 2021, then surged by 1,430.46% to $11.6 million in 2022, then crashed by 135.39% to -$4.1 million in 2023, then increased by 28.93% to -$2.9 million in 2024, then soared by 71.21% to $13.8 million in 2025.
  • Its Change in Receivables stands at $13.8 million for Q3 2025, versus -$12.3 million for Q2 2025 and $8.1 million for Q1 2025.